Company Directory - Ocular Therapeutix, Inc.
Company Details - Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
WebsiteOcular Therapeutix, Inc. is a biotechnology company that specializes in the development of sustained-release therapies for the treatment of ophthalmic diseases and conditions. The company is committed to innovating and providing solutions for patients with significant unmet medical needs in the eye care sector.
CCI Score
CCI Score: Ocular Therapeutix, Inc.
-26.59
0.01%
Latest Event
Workforce Reduction Raises Labor Concerns
Ocular Therapeutix, Inc. announced plans to eliminate 13% of its full-time workforce, primarily affecting its research & development and technological operations teams, as part of a strategic restructuring to focus on its wet AMD therapeutic.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
Ocular Therapeutix, Inc. is currently rated as an Accomplice.
Latest Events
- JUN052024
Ocular Therapeutix, Inc. announced plans to eliminate 13% of its full-time workforce, primarily affecting its research & development and technological operations teams, as part of a strategic restructuring to focus on its wet AMD therapeutic.
-70
Labor Relations and Human Rights Practices
April 8
The decision to cut 13% of the workforce, primarily in critical R&D and tech operations, undermines worker rights and job security. This move, while part of a restructuring effort to boost clinical development, disproportionately harms employees, reflecting broader issues of labor exploitation and diminished protections for workers.
- JUN032024
On June 3, 2024, Ocular Therapeutix laid off 13% of its employees—amounting to 37 full-time positions—primarily in research and development and technical operations. The move was part of a strategic shift to focus resources on the clinical development of its investigational intravitreal implant for retinal diseases, a decision that raises concerns about the treatment and security of its workforce.
-50
Labor Relations and Human Rights Practices
April 8
The decision to cut 13% of the workforce, especially targeting key areas such as research and development, undermines worker rights and stability. From a progressive anti-fascist perspective, such actions contribute to a trend of corporate practices that disregard the welfare of employees in favor of narrow business strategies, and thus are severely rated.
- JAN012024
The OpenSecrets profile for Ocular Therapeutix shows that the company has not reported lobbying on specific bills in 2024, indicating limited engagement in direct political influence. This limited lobbying activity may reduce risks of corporate complicity in efforts that could support authoritarian policies.
+30
Political Contributions and Lobbying Efforts
April 8
According to the OpenSecrets profile, Ocular Therapeutix has not reported active lobbying on specific bills in 2024. This lack of direct lobbying reduces the potential for the company to exert undue influence on legislative processes, a factor valued positively from an anti-authoritarian perspective. The transparency provided by this publicly accessible profile further supports accountability.
- JAN012024
Ocular Therapeutix spent $20,000 on lobbying activities in 2024, as reported by OpenSecrets. This expenditure reflects the company’s engagement in political influence activities that can potentially allow corporate interests to shape public policy.
-30
Political Contributions and Lobbying Efforts
April 8
The report indicates that Ocular Therapeutix spent $20,000 on lobbying in 2024. From an anti-fascist perspective, such corporate lobbying efforts are viewed as attempts to exert undue influence on public policy and democratic processes, contributing to corporate capture of the political landscape.
- JUL072017
A lawsuit alleges that Ocular Therapeutix, Inc. and four executives misled investors about the quality and future promise of their ophthalmic drug, Dextenza, by downplaying manufacturing issues under FDA investigation. The suit claims that more than half of produced lots were substandard, leading to a significant drop in the company's stock price.
-50
Business Practices and Ethical Responsibility
April 8
The allegations suggest that the company engaged in unethical business practices by misrepresenting the quality and regulatory compliance of its product. Misleading investors about manufacturing standards not only constitutes a breach of fiduciary duty but also erodes public trust in corporate governance, reflecting a problematic business ethics approach.
Lawsuit: Investors Blind to Ocular Therapeutix's Quality Issues
Alternatives
Corporation
34.21
Brentford, United Kingdom
18.03
Bagsværd, Denmark
16.06
Darmstadt, Germany
12.29
Dublin, Ireland
-16.04
Corporation
-49.80
Belgium (Ghent), Belgium
79.03
Geneva, Switzerland
66.60
Raleigh, USA
56.52
Canada
49.33
Industries
- 325413
- In-Vitro Diagnostic Substance Manufacturing
- 423450
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- 541711
- Research and Development in Biotechnology